why choose us

First received: August 18, 2022

Clinical Trial: Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events

Study Status: Completed

Recruit Status: Completed

Condition: Venous Thromboembolism
Anticoagulant-induced Bleeding
Venous Thromboses
Pulmonary Emb

Study Type: Interventional


Official Title: Rivaroxaban Plus Aspirin Versus Acenocoumarol to Manage Recurrent Venous Thromboembolic Events Despite Systemic Anticoagulation With Rivaroxaban

Brief Summary: Venous thromboembolism affects around 10 million people per year worldwide, however, despite its high incidence, there is no systematic review or randomized trial focused on the treatment of patients with recurrent deep vein thrombosis (DVT) and/or or pulmonary embolism (PE) during anticoagulant treatment. The objective was to compare the use of Rivaroxaban plus Aspirin versus Acenocoumarol in patients with recurrent venous thromboembolism treated with rivaroxaban.

Read more